ECSP055748A - Composiciones de liberacion controlada - Google Patents

Composiciones de liberacion controlada

Info

Publication number
ECSP055748A
ECSP055748A EC2005005748A ECSP055748A ECSP055748A EC SP055748 A ECSP055748 A EC SP055748A EC 2005005748 A EC2005005748 A EC 2005005748A EC SP055748 A ECSP055748 A EC SP055748A EC SP055748 A ECSP055748 A EC SP055748A
Authority
EC
Ecuador
Prior art keywords
matrix
release
agent
controlled release
release compositions
Prior art date
Application number
EC2005005748A
Other languages
English (en)
Inventor
Vincent Lenaerts
Patricia Laure Quadji-Njiki
Jonathan Bacon
Rachid Ouzerourou
Sonia Gervais
Miloud Rahmouni
Original Assignee
Labopharm Inc
Labopharm Europe Ltd
Labopharm Barbados Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc, Labopharm Europe Ltd, Labopharm Barbados Ltd filed Critical Labopharm Inc
Publication of ECSP055748A publication Critical patent/ECSP055748A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulación de dosis sólida que tiene un núcleo con un agente farmacológico disperso en un primer aglomerante de liberación controlada del cual la liberación del agente es relativamente lenta; y una cubierta formada sobre el núcleo y que tiene un agente disperso en un segundo aglomerante de liberación controlada del cual la liberación del agente es relativamente rápida. El primer aglomerante puede ser un almidón elevado en amilosa degradada y el segundo aglomerante puede ser una mezcla de acetato de polivinilo y polivinilpirrolidona.
EC2005005748A 2002-10-25 2005-04-25 Composiciones de liberacion controlada ECSP055748A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28102602A 2002-10-25 2002-10-25
US50906202P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
ECSP055748A true ECSP055748A (es) 2005-08-11

Family

ID=34976756

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005748A ECSP055748A (es) 2002-10-25 2005-04-25 Composiciones de liberacion controlada

Country Status (18)

Country Link
EP (1) EP1558935B1 (es)
JP (1) JP2006507276A (es)
KR (1) KR101120729B1 (es)
AT (1) ATE400819T1 (es)
AU (1) AU2003275854B9 (es)
BR (1) BR0315657A (es)
CA (1) CA2503361C (es)
DE (1) DE60322091D1 (es)
DK (1) DK1558935T3 (es)
EC (1) ECSP055748A (es)
ES (1) ES2310686T3 (es)
MX (1) MXPA05004410A (es)
NO (1) NO20052515D0 (es)
NZ (1) NZ539869A (es)
PT (1) PT1558935E (es)
RU (1) RU2333745C2 (es)
SI (1) SI1558935T1 (es)
WO (1) WO2004038428A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
NZ565108A (en) 2005-07-07 2011-10-28 Farnam Co Inc Sustained release pharmaceutical compositions for highly water soluble drugs
WO2007048219A2 (en) 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
PT1931346E (pt) * 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
CN100437113C (zh) * 2006-04-11 2008-11-26 汪运山 一种检测血液中非那西丁与醋氨酚浓度比值的试剂盒
HUE029173T2 (hu) 2006-04-26 2017-02-28 Alphapharm Pty Ltd Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
CN100387988C (zh) * 2006-07-25 2008-05-14 山东省医药工业研究所 一种布洛伪麻那敏复方制剂的含量检测方法
PL2120878T3 (pl) 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
JP5453280B2 (ja) * 2007-10-16 2014-03-26 ラボファーム インコーポレイテッド アセトアミノフェンおよびトラマドールを持続的に放出するための二層組成物
CN102046170B (zh) 2008-05-27 2012-11-28 墨尔本大学 治疗患有咽鼓管功能障碍的哺乳动物的方法
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011130834A1 (en) * 2010-04-23 2011-10-27 Labopharm Inc. Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
PT1009387E (pt) * 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US6897205B2 (en) * 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet

Also Published As

Publication number Publication date
EP1558935A2 (en) 2005-08-03
KR20050088281A (ko) 2005-09-05
MXPA05004410A (es) 2005-11-23
DK1558935T3 (da) 2008-11-17
WO2004038428A2 (en) 2004-05-06
AU2003275854A1 (en) 2004-05-13
ATE400819T1 (de) 2008-07-15
RU2005115883A (ru) 2006-01-27
NZ539869A (en) 2007-09-28
JP2006507276A (ja) 2006-03-02
NO20052515L (no) 2005-05-25
RU2333745C2 (ru) 2008-09-20
AU2003275854B9 (en) 2009-08-27
PT1558935E (pt) 2008-10-16
WO2004038428A3 (en) 2005-06-09
ES2310686T3 (es) 2009-01-16
DE60322091D1 (de) 2008-08-21
NO20052515D0 (no) 2005-05-25
HK1086475A1 (zh) 2006-09-22
CA2503361C (en) 2012-02-28
EP1558935B1 (en) 2008-07-09
KR101120729B1 (ko) 2012-04-23
AU2003275854B2 (en) 2008-09-11
SI1558935T1 (sl) 2008-12-31
CA2503361A1 (en) 2004-05-06
BR0315657A (pt) 2005-09-13

Similar Documents

Publication Publication Date Title
ECSP055748A (es) Composiciones de liberacion controlada
ES2101082T3 (es) Composiciones de liberacion controlada.
NL2000281A1 (nl) Vaste farmaceutische samenstellingen die pregabaline bevatten.
ATE512659T1 (de) Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie
HRP20050625A2 (hr) Tablete bupropion hidroklorida s promijenjenim otpuštanjem
AR001405A1 (es) Formulación oral de 2-metil-tieno-beno-diacepina.
NZ515359A (en) Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
HUP0401714A2 (hu) Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái
TWI235068B (en) Sustained-release pharmaceutical composition
MX9707585A (es) Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
GEP20074022B (en) Pharmaceutical formulations comprising oxycodone and naloxone
ATE268593T1 (de) Bupropionhydrochlorid enthaltende tabletten mit gesteuerter wirkstoffabgabe
HK1051487A1 (zh) 含有阿片样激动剂和拮抗剂的控释组合物
ATE455538T1 (de) Retardtabletten mit hydromorphon
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
AU2002233271A1 (en) Substitued oxazoles and thiazoles as hppar alpha agonists
DE69512638D1 (de) Schnell auflösende orale darreichungsform
MY142195A (en) Controlled-release compositions
UA86929C2 (ru) Композиция с контролируемым высвобождением
WO2007025182A3 (en) Drug compositions containing controlled release hypromellose matrices
BRPI0315657B8 (pt) formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
SE0104327D0 (sv) New film coating
ECSP961693A (es) Formulacion oral de 2- metil-tieno-benzodiaceptina